Journal article
Overcoming Tagraxofusp-Erzs MonotherapyResistance in Blastic Plasmacytoid DendriticCell Neoplasm (BPDCN) in a Real-WorldClinical Setting
Journal of Immunotherapy and Precision Oncology, Vol.7(3), pp.205-209
08/01/2024
DOI: 10.36401/JIPO-23-43
PMCID: PMC11361340
PMID: 39219995
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic malignancy with limitedtreatment options. Currently, standard treatment strategies include clinical trials; chemotherapy regimens such as hyperfractionatedcyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD); and tagraxofusp-erzs (TAG, previously SL-401) which isthe first-in-class targeted therapy against CD123. TAG received Food and Drug Administration approval for frontline BPDCNtreatment in December 2018 and has increasingly become an alternative to chemotherapy, offering potentially more effectiveand less toxic options. However, despite promising results, there are still patients who may be resistant to TAG monotherapyand/or who respond but eventually relapse. Herein, we discuss an important patient case of BPDCN treated with TAG and reviewBPDCN treatment strategies.
Details
- Title: Subtitle
- Overcoming Tagraxofusp-Erzs MonotherapyResistance in Blastic Plasmacytoid DendriticCell Neoplasm (BPDCN) in a Real-WorldClinical Setting
- Creators
- Prajwal Dhakal - University of IowaMario Sy - University of IowaGrerk Sutamtewagul - University of IowaEric Mou - University of IowaNanmeng Yu - University of IowaNaveen Pemmaraju - The University of Texas MD Anderson Cancer Center
- Resource Type
- Journal article
- Publication Details
- Journal of Immunotherapy and Precision Oncology, Vol.7(3), pp.205-209
- DOI
- 10.36401/JIPO-23-43
- PMID
- 39219995
- PMCID
- PMC11361340
- NLM abbreviation
- J Immunother Precis Oncol
- ISSN
- 2666-2345
- eISSN
- 2590-017X
- Publisher
- Innovative Healthcare Institute
- Number of pages
- 5
- Language
- English
- Date published
- 08/01/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984786448902771
Metrics
4 Record Views